tiprankstipranks
Advertisement
Advertisement

KLRS Stock Latest News

Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
RatingsKalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
12d ago
KLRS
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
PremiumThe Fly
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
12d ago
KLRS
Kalaris Therapeutics sees cash runway into 4Q27
PremiumThe Fly
Kalaris Therapeutics sees cash runway into 4Q27
12d ago
KLRS
Kalaris Updates TH103 Strategy and Highlights Cash Runway
PremiumCompany Announcements
Kalaris Updates TH103 Strategy and Highlights Cash Runway
20d ago
8K
KLRS
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
PremiumWeekend Updates
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
3M ago
BRO
ANNX
Kalaris Therapeutics initiated with a Buy at Chardan
PremiumThe FlyKalaris Therapeutics initiated with a Buy at Chardan
3M ago
KLRS
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
Premium
Ratings
Early Clinical Strength and Durability of TH103 Underpin Buy Rating on Kalaris Therapeutics
3M ago
KLRS
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
Premium
Company Announcements
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing
3M ago
8K
KLRS
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
PremiumThe Fly
Kalaris Therapeutics price target raised to $26 from $20 at Citizens
3M ago
KLRS
Kalaris Therapeutics announces $50M private placement
PremiumThe Fly
Kalaris Therapeutics announces $50M private placement
3M ago
KLRS
Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
PremiumThe Fly
Kalaris Therapeutics expects cash, equivalents to fund operations into 3Q27
3M ago
KLRS
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
PremiumCompany Announcements
Kalaris Therapeutics Announces Positive Phase 1a Trial Data
3M ago
8K
KLRS
Kalaris Therapeutics announces initial data from TH103 trial
PremiumThe FlyKalaris Therapeutics announces initial data from TH103 trial
3M ago
KLRS
Kalaris Therapeutics Reports Q3 2025 Financial Progress
Premium
Company Announcements
Kalaris Therapeutics Reports Q3 2025 Financial Progress
4M ago
KLRS
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
Premium
Ratings
Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
5M ago
KLRS
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
PremiumThe Fly
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
5M ago
KLRS
Kalaris Therapeutics Appoints New CFO Matthew Gall
PremiumCompany Announcements
Kalaris Therapeutics Appoints New CFO Matthew Gall
5M ago
8K
KLRS
Kalaris Therapeutics appoints Gall as Chief Financial Officer
PremiumThe Fly
Kalaris Therapeutics appoints Gall as Chief Financial Officer
5M ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
PremiumThe Fly
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
5M ago
KLRS
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
PremiumRatingsOptimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
6M ago
KLRS
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
Premium
The Fly
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
6M ago
KLRS
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
7M ago
KLRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >